FDAAA Cornucopia: REMS To Be Used Sparingly; Trial Database On Schedule

FDA will use its authority to require risk evaluation and mitigation strategies judiciously, according to Chief Medical Officer and CDER Acting Director Janet Woodcock

More from Archive

More from Pink Sheet